Patents Assigned to Massachusetts General Hospital
-
Publication number: 20200338087Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate STK inhibitors of Formula (III)).Type: ApplicationFiled: April 19, 2019Publication date: October 29, 2020Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Alykhan Shamji, Thomas Sundberg, Nathanael S. Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
-
Publication number: 20200323945Abstract: The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.Type: ApplicationFiled: April 6, 2020Publication date: October 15, 2020Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Ronald G. Tompkins, A. Aria Tzika, Yong-Ming Yu, Laurence Rahme, Jeevendra A. Martyn
-
Publication number: 20200312426Abstract: Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.Type: ApplicationFiled: March 6, 2020Publication date: October 1, 2020Applicants: NemaMetrix, Inc, The General Hospital Corportation, dba Massachusetts General HospitalInventors: David Kokel, Randall T. Peterson, Giancarlo Bruni, Andrea Velenich
-
Patent number: 10595794Abstract: An animal, specimen, or imaging phantom is imaged in precise increments over at least 360 degrees. The animal, specimen, or imaging phantom is supported within a subject holder. The subject holder has an elongated portion or tube for holding securely the animal, specimen or imaging phantom. The subject holder is connected to an actuator motor driver. The actuator motor driver causes the subject holder to rotate at the precise increments, and an image of the animal, specimen, or imaging phantom is captured at each increment. The subject holder limits movement of the subject being imaged at each increment.Type: GrantFiled: July 9, 2015Date of Patent: March 24, 2020Assignees: AUBURN UNIVERSITY, MASSACHUSETTS GENERAL HOSPITALInventors: Peter Panizzi, Andrew D. Brannen, Robert D. Arnold, Matthias Nahrendorf
-
Publication number: 20200087236Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: ApplicationFiled: June 15, 2018Publication date: March 19, 2020Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei TSAI, Stephen J. HAGGARTY, Debasis PATNAIK, Ping-Chieh PAO
-
Publication number: 20190343842Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate STK inhibitors of Formula (III)).Type: ApplicationFiled: April 19, 2019Publication date: November 14, 2019Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Alykhan Shamji, Thomas Sundberg, Nathanael S. Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
-
Publication number: 20190264227Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.Type: ApplicationFiled: March 20, 2019Publication date: August 29, 2019Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a Massachusetts General HospitalInventors: Johan Karl Olov Skog, Casey Maguire
-
Publication number: 20190175646Abstract: Described herein are methods and compositions relating to the treatment of benign skin tumors and/or malformations (e.g., seborrheic keratosis) by administering a proteasomal inhibitor and/or cationic inhibitor in combination with Zn2+ or Cu2+.Type: ApplicationFiled: November 28, 2016Publication date: June 13, 2019Applicant: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITALInventors: Anna MANDINOVA, Victor Allen NEEL
-
Patent number: 10301294Abstract: Disclosed are compounds that can be used for treating tuberculosis.Type: GrantFiled: March 12, 2014Date of Patent: May 28, 2019Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS GENERAL HOSPITAL, BRIGHAM AND WOMEN'S HOSPITALInventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
-
Patent number: 10295624Abstract: A method of determining a decoupling matrix of a decoupling system for an array of coils of a parallel transmission magnetic resonance imaging (MRI) system includes obtaining impedance matrix data for the array of coils without the decoupling system, determining, based on the impedance matrix data for the array of coils, an objective function representative of deviation from a decoupled operating condition for the array of coils in which the array of coils are decoupled via the decoupling system, and defining, with a processor, a decoupling matrix representative of a set of impedances of the decoupling system with an iterative procedure that optimizes elements of the decoupling matrix to minimize the objective function and reach the decoupled operating condition.Type: GrantFiled: June 14, 2013Date of Patent: May 21, 2019Assignees: Massachusetts Institute of Technology, Massachusetts General Hospital, Siemens Healthcare GmbHInventors: Elfar Adalsteinsson, Luca Daniel, Bastien Guerin, Zohaib Mahmood, Markus Vester, Lawrence Wald
-
Publication number: 20190144867Abstract: A method for inhibiting metastasis of cancer cells is provided. Inhibitors of heparan sulfate (HS) or hyaluronic acid (HA) are applied to a tumor or a surgical location after removal of the bulk of the tumor. The inhibitors enzymatically cleave surface HS or HA; genetically modify cancer cells to decrease HS or HA production or interfere with the signaling pathway between HS or HA and a MMP or syndecan.Type: ApplicationFiled: September 19, 2016Publication date: May 16, 2019Applicants: Research Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center, The General Hospital Corporation D/B/A Massachusetts General HospitalInventors: John M. TARBELL, Lance L. MUNN, Henry QAZI, Zhongdong SHI
-
Publication number: 20190099435Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.Type: ApplicationFiled: August 16, 2018Publication date: April 4, 2019Applicants: Children's Hospital Medical Center, The General Hospital Corporation d/b/a Massachusetts General Hospital, Instituto Nacional de Ciencias Medicas Y NutricionInventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
-
Patent number: 10238440Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.Type: GrantFiled: January 2, 2014Date of Patent: March 26, 2019Assignees: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, THE GENERAL HOSPITAL CORPORATION DBA MASSACHUSETTS GENERAL HOSPITALInventors: Stanley E Asnis, Peter D Asnis
-
Patent number: 10228313Abstract: In accordance with an embodiment of the invention, there is provided a method for: a) high-throughput, multiplexed, affinity-based separation of proteins—especially low abundance proteins—from complex biological mixtures such as serum; and b) high-throughput, multiplexed, affinity-based separation of cells—especially rare cells—from complex biological mixtures such as blood or blood fractions. The separation of proteins or cells is achieved based on differential binding to affinity-capture beads of different sizes and then sorting the protein-bound or cell-bound beads using the concept of centrifugal-induced Dean migration in a spiral microfluidic device. This method enables continuous-flow, high throughput affinity-separation of milligram-scale protein samples or millions of cells in minutes after binding.Type: GrantFiled: October 23, 2015Date of Patent: March 12, 2019Assignees: Massachusetts Institute of Technology, The Massachusetts General HospitalInventors: Aniruddh Sarkar, Han Wei Hou, Jongyoon Han, Galit Alter
-
Publication number: 20190038656Abstract: Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).Type: ApplicationFiled: October 3, 2016Publication date: February 7, 2019Applicants: Memorial Slooan-Kettering Cancer Center, The General Hospital Corporation d/b/a Massachusetts General Hospital, East Carolina UniversityInventors: Derek Shieh Tan, Cheng Ji, Indrajeet Sharma, Debarshi Pratihar, James P. Coleman, Everett C. Pesci, Laurence G. Rahme
-
Publication number: 20190038679Abstract: Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.Type: ApplicationFiled: February 8, 2017Publication date: February 7, 2019Applicant: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITALInventors: Cammie LESSER, Analise REEVES
-
Patent number: 10197646Abstract: A magnetic resonance imaging (MRI) system includes a plurality of transmitters to generate a parallel transmission radio frequency (RF) pulse, an array of coils coupled to the plurality of transmitters to apply the parallel transmission RF pulse to a subject, and a decoupling system connected to the plurality of transmitters and the array of coils. The decoupling system includes a plurality of hybrid couplers, each hybrid coupler of the plurality of hybrid couplers being coupled to a respective pair of the plurality of transmitters and to a respective pair of the array of coils. The plurality of hybrid couplers are configured to diagonalize an impedance matrix of the plurality of coils.Type: GrantFiled: May 6, 2015Date of Patent: February 5, 2019Assignees: Siemens Aktiengesellschaft, Massachusetts Institute of Technology, Massachusetts General Hospital CorporationInventors: Elfar Adalsteinsson, Luca Daniel, Bastien Guerin, Boris Keil, Zohaib Mahmood, Markus Vester, Lawrence Wald
-
Publication number: 20180327750Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: April 3, 2018Publication date: November 15, 2018Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Publication number: 20180303373Abstract: A system and method for imaging in connection with electrical currents includes nanoparticles introduced into a region in which the electrical currents are present. A low-field magnetic resonance imaging (MRI) scanner detects an effect of a magnetic field generated by interaction of the nanoparticles with the electrical currents in the region. The MRI scanner operates at a magnetic field intensity below a level at which the nanoparticles would be magnetically saturated.Type: ApplicationFiled: April 21, 2017Publication date: October 25, 2018Applicants: The Charles Stark Draper Laboratory, Inc., The Massachusetts General HospitalInventors: Daniel K. Freeman, Matthew Rosen
-
Publication number: 20180280551Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specific ally conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.Type: ApplicationFiled: October 1, 2016Publication date: October 4, 2018Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Mohammad Rashidian, Hidde L. Ploegh, Neil Vasdev, Huan Steven Liang